series-b
Stage
About
Oblenio Bio develops LBL-051, a tri-specific T-cell engager antibody therapy targeting BCMA, CD19, and CD3 to deplete pathological B-cells and plasma cells, aiming to treat refractory autoimmune diseases and achieve long-term drug-free remission.
Explore Oblenio Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.